Author

Dhananjay Bakhle

Observed name: D. Bakhle

Institution: Lupin Pharmaceuticals (India)

Observed institutions: Lupin Pharmaceuticals (India), Post Graduate Institute of Medical Education and Research

ORCID: 0000-0001-8701-9561

Observed ORCID: 0000-0001-8701-9561

OpenAlex ID: A5027031788

Discovery of Novel, Potent, Brain-Permeable, and Orally Efficacious Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptor [4-(5-(4-Chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide]: Structure–Activity Relationship and Preclinical Characterization

2019 · Neelima Sinha, Navnath P. Karche, et al. · Journal of Medicinal Chemistry · 30

A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration

2022 · Ramandeep Singh, Rohan Chauhan, et al. · Indian Journal of Ophthalmology · 26

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis

2019 · Hisashi Yamanaka, Naoyuki Kamatani, et al. · Rheumatology and Therapy · 20

Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization

2020 · Navnath P. Karche, Mandar Bhonde, et al. · Bioorganic & Medicinal Chemistry · 15

Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure–Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides

2020 · Vidya Ramdas, Rashmi Talwar, et al. · Journal of Medicinal Chemistry · 14

Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro-N-(2′-methyl-3′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide. Structure–Activity Relationship and Preclinical Characterization

2021 · Nilesh Raghunath Khedkar, Nageswara Rao Irlapatti, et al. · Journal of Medicinal Chemistry · 9

An Open-Label, Randomized, Single-Dose, Crossover, Comparative Pharmacokinetics Study of YLB113 and the Etanercept Reference Product in Healthy Adult Male Subjects

2020 · Mustafa Shennak, Rana Al-Jaouni, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 9

Discovery of LNP1892: A Precision Calcimimetic for the Treatment of Secondary Hyperparathyroidism

2023 · Manojkumar R. Shukla, Gayathri Sadasivam, et al. · Journal of Medicinal Chemistry · 7

Lower injection‐site reactions and long‐term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113 : Results from a post‐hoc analysis of a double‐blind, randomized, phase III comparative study and its open‐label extension in patients with rheumatoid arthritis

2022 · Hisashi Yamanaka, Yoshiya Tanaka, et al. · International Journal of Rheumatic Diseases · 6

Comparison of Efficacy and Safety of Lupin’s Pegfilgrastim with Neulastim® as an Adjunct to Chemotherapy in Patients with Non Myeloid Malignancies: A Randomised Phase III Clinical Study

2022 · Minish Jain, Sharad Desai, et al. · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · 1

Ab0416 a Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of Ylb113 and Etanercept Reference Product for the Treatment of Patients With Active Rheumatoid Arthritis

2019 · Hisashi Yamanaka, Naoyuki Kamatani, et al. · Annals of the Rheumatic Diseases · 1

A randomised, crossover study establishing pharmacokinetic and pharmacodynamic equivalence between Lupin’s Pegfilgrastim and Neulasta ® in healthy subjects

2022 · Shardul Doctor, Ravi Kasibhatta, et al.

Pos0598 Comparison of Injection Site Reactions and Injection Site Erythema Between Ylb113 and Etanercept Reference Product From Phase 3 Active Comparator Study (study No. Ylb113-002)

2021 · D. Stefanidis, U. G, et al. · Annals of the Rheumatic Diseases

Pos0604 Long Term Safety and Tolerability With Etanercept Biosimilar (ylb113), Results From a 2-year Open Label Extension Study (study No. Ylb113-003)

2021 · Y. Hisashi, Y. Tanaka, et al. · Annals of the Rheumatic Diseases

Works count: 15

Citation count: 138

H-index: 7

I10-index: 5